Anthem Biosciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Anthem Biosciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 93% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 36.2 times by its yearly operating cash. Higher than 90% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹89Over the last 3 years, every ₹100 of reported profit came with ₹89 of operating cash.
Lower than 61% of Healthcare companies in India.
Self-Funding Ratio
1.6×Over the last 3 years its own operating cash covered its investment spending (capex) 1.6 times.
Higher than 62% of Healthcare companies in India.
Cash Locked Ratio
₹28For every ₹100 of sales, ₹28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹28 tied up three years earlier.
More money tied up than 58% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹19Sales grew 101% in 3 years; of every extra ₹100 of sales, ₹19 became extra profit.
Higher than 56% of Healthcare companies in India.
Asset Productivity Ratio
+101% / +70%In 3 years sales changed by +101% while total assets changed by +70%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
36.2×Debt due within a year is covered 36.2 times by its yearly operating cash.
Higher than 90% of Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 68% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 93% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Anthem Biosciences Limited owes ₹0.11 for every ₹1 it owns. Net profit rose 31% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
78.9Investors pay ₹78.9 for every ₹1 of Anthem Biosciences Limited's yearly profit, higher than 85% of Healthcare companies in India.
P/B ratio
14.78The share price is 14.78 times Anthem Biosciences Limited's book value per share, higher than 93% of Healthcare companies in India.
Market cap
₹44,979 CrThe total market value of all of Anthem Biosciences Limited's shares at today's price (share price × number of shares), larger than 87% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹3,043 CrWhat Anthem Biosciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹54.16Net worth divided by the number of shares. The share price of ₹800.75 is 14.8 times this, which is the P/B above.
Return on equity (ROE)
18.7%Anthem Biosciences Limited earned 18.7% on its shareholders' money over the last year, higher than 76% of Healthcare companies in India.
Owes vs Owns
0.11×Anthem Biosciences Limited owes ₹0.11 for every ₹1 it owns (low), lower than 98% of Healthcare companies in India.
Dividend yield
0.23%Anthem Biosciences Limited pays 0.23% of its share price as dividends a year, lower than 67% of dividend-paying Healthcare companies in India.
Revenue growth
+15%Revenue rose 15% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Profit growth
+31%Net profit rose 31% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit margin
27.9%Anthem Biosciences Limited keeps ₹28 of every ₹100 of revenue as net profit.
Cash quality
1.4×Cash from Anthem Biosciences Limited's business was 1.4× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
107.8×Anthem Biosciences Limited's operating profit covered its interest costs 107.8 times in the year to Mar 2026.
Cash vs debt
Net cashAnthem Biosciences Limited held ₹885 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Anthem Biosciences Limited's P/E ratio?
Investors pay ₹78.9 for every ₹1 of Anthem Biosciences Limited's yearly profit, higher than 85% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Anthem Biosciences Limited: ₹44,979 Cr ÷ ₹3,043 Cr (31 Mar 2026) = 14.8.
What is Anthem Biosciences Limited's return on equity?
Anthem Biosciences Limited earned 18.7% on its shareholders' money over the last year, higher than 76% of Healthcare companies in India.
How much does Anthem Biosciences Limited owe compared with what it owns?
Anthem Biosciences Limited owes ₹0.11 for every ₹1 it owns (low), lower than 98% of Healthcare companies in India.
Does Anthem Biosciences Limited pay a dividend?
Yes. Anthem Biosciences Limited pays 0.23% of its share price as dividends a year, lower than 67% of dividend-paying Healthcare companies in India.
Is Anthem Biosciences Limited's revenue growing?
Revenue rose 15% in the year to Mar 2026, and grew 26% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.